Inhibikase Therapeutics Stock Forecast - Naive Prediction
| IKT Stock | USD 1.74 0.06 3.33% |
Inhibikase Stock outlook is based on your current time horizon.
At this time, The RSI of Inhibikase Therapeutics' share price is at 52. This usually indicates that the stock is in nutural position, most likellhy at or near its resistance level. The main idea of RSI analysis is to track how fast people are buying or selling Inhibikase Therapeutics, making its price go up or down. Momentum 52
Impartial
Oversold | Overbought |
EPS Estimate Current Year (0.51) | EPS Estimate Next Year (0.72) | Wall Street Target Price 8 | Quarterly Revenue Growth (1.00) |
Using Inhibikase Therapeutics hype-based prediction, you can estimate the value of Inhibikase Therapeutics from the perspective of Inhibikase Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The Naive Prediction forecasted value of Inhibikase Therapeutics on the next trading day is expected to be 1.70 with a mean absolute deviation of 0.08 and the sum of the absolute errors of 4.62. Inhibikase Therapeutics after-hype prediction price | USD 1.74 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Inhibikase | Build AI portfolio with Inhibikase Stock |
Inhibikase Therapeutics Additional Predictive Modules
Most predictive techniques to examine Inhibikase price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Inhibikase using various technical indicators. When you analyze Inhibikase charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Forecasting cash, or other financial indicators, requires analysts to apply different statistical methods, techniques, and algorithms to find hidden patterns within the Inhibikase Therapeutics' financial statements to predict how it will affect future prices.
Cash | First Reported 2017-03-31 | Previous Quarter 77.7 M | Current Value 38.3 M | Quarterly Volatility 23.7 M |
Inhibikase Therapeutics Naive Prediction Price Forecast For the 27th of January
Given 90 days horizon, the Naive Prediction forecasted value of Inhibikase Therapeutics on the next trading day is expected to be 1.70 with a mean absolute deviation of 0.08, mean absolute percentage error of 0.01, and the sum of the absolute errors of 4.62.Please note that although there have been many attempts to predict Inhibikase Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Inhibikase Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Inhibikase Therapeutics Stock Forecast Pattern
| Backtest Inhibikase Therapeutics | Inhibikase Therapeutics Price Prediction | Buy or Sell Advice |
Inhibikase Therapeutics Forecasted Value
In the context of forecasting Inhibikase Therapeutics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Inhibikase Therapeutics' downside and upside margins for the forecasting period are 0.02 and 6.49, respectively. We have considered Inhibikase Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Inhibikase Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Inhibikase Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 113.3292 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.0758 |
| MAPE | Mean absolute percentage error | 0.0452 |
| SAE | Sum of the absolute errors | 4.6211 |
Predictive Modules for Inhibikase Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Inhibikase Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Inhibikase Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Inhibikase Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Inhibikase Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Inhibikase Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Inhibikase Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Inhibikase Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Inhibikase Therapeutics' historical news coverage. Inhibikase Therapeutics' after-hype downside and upside margins for the prediction period are 0.09 and 6.55, respectively. We have considered Inhibikase Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Inhibikase Therapeutics is dangerous at this time. Analysis and calculation of next after-hype price of Inhibikase Therapeutics is based on 3 months time horizon.
Inhibikase Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Inhibikase Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Inhibikase Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Inhibikase Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.39 | 4.79 | 0.00 | 0.05 | 18 Events / Month | 5 Events / Month | In about 18 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
1.74 | 1.74 | 0.00 |
|
Inhibikase Therapeutics Hype Timeline
On the 26th of January Inhibikase Therapeutics is traded for 1.74. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.05. Inhibikase is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is currently at 0.39%. %. The volatility of related hype on Inhibikase Therapeutics is about 3548.15%, with the expected price after the next announcement by competition of 1.79. About 13.0% of the company shares are held by company insiders. The book value of Inhibikase Therapeutics was currently reported as 1.07. The company recorded a loss per share of 0.04. Inhibikase Therapeutics had not issued any dividends in recent years. The entity had 1:6 split on the 30th of June 2023. Considering the 90-day investment horizon the next forecasted press release will be in about 18 days. Check out Historical Fundamental Analysis of Inhibikase Therapeutics to cross-verify your projections.Inhibikase Therapeutics Related Hype Analysis
Having access to credible news sources related to Inhibikase Therapeutics' direct competition is more important than ever and may enhance your ability to predict Inhibikase Therapeutics' future price movements. Getting to know how Inhibikase Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Inhibikase Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| TTRX | Turn Therapeutics Common | 0.12 | 2 per month | 7.17 | 0.03 | 18.15 | (11.81) | 42.47 | |
| CGTX | Cognition Therapeutics | (0.39) | 2 per month | 0.00 | (0.07) | 8.89 | (8.38) | 24.96 | |
| SRZN | Surrozen | 0.04 | 10 per month | 4.12 | 0.11 | 12.23 | (6.75) | 34.29 | |
| TVGN | Tevogen Bio Holdings | 0.03 | 9 per month | 0.00 | (0.16) | 10.00 | (8.89) | 26.81 | |
| GLSI | Greenwich Lifesciences | (0.39) | 2 per month | 4.63 | 0.23 | 18.12 | (8.50) | 36.10 | |
| EXOZ | eXoZymes | 1.75 | 10 per month | 3.98 | 0.0001 | 11.43 | (7.23) | 26.73 | |
| ESLA | Estrella Immunopharma | 0.04 | 8 per month | 0.00 | (0.07) | 12.23 | (15.49) | 50.95 | |
| ATOS | Atossa Genetics | 0.04 | 8 per month | 0.00 | (0.17) | 6.45 | (6.25) | 20.34 | |
| AGEN | Agenus Inc | 0.01 | 9 per month | 0.00 | (0.1) | 6.63 | (6.05) | 30.06 | |
| ENTX | Entera Bio | 0.10 | 20 per month | 0.00 | (0.13) | 8.57 | (8.05) | 22.41 |
Other Forecasting Options for Inhibikase Therapeutics
For every potential investor in Inhibikase, whether a beginner or expert, Inhibikase Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Inhibikase Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Inhibikase. Basic forecasting techniques help filter out the noise by identifying Inhibikase Therapeutics' price trends.Inhibikase Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Inhibikase Therapeutics stock to make a market-neutral strategy. Peer analysis of Inhibikase Therapeutics could also be used in its relative valuation, which is a method of valuing Inhibikase Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Inhibikase Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how Inhibikase Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Inhibikase Therapeutics shares will generate the highest return on investment. By undertsting and applying Inhibikase Therapeutics stock market strength indicators, traders can identify Inhibikase Therapeutics entry and exit signals to maximize returns.
Inhibikase Therapeutics Risk Indicators
The analysis of Inhibikase Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Inhibikase Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting inhibikase stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 3.28 | |||
| Semi Deviation | 4.02 | |||
| Standard Deviation | 4.69 | |||
| Variance | 22.0 | |||
| Downside Variance | 16.84 | |||
| Semi Variance | 16.12 | |||
| Expected Short fall | (3.70) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Inhibikase Therapeutics
The number of cover stories for Inhibikase Therapeutics depends on current market conditions and Inhibikase Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Inhibikase Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Inhibikase Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Inhibikase Therapeutics Short Properties
Inhibikase Therapeutics' future price predictability will typically decrease when Inhibikase Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Inhibikase Therapeutics often depends not only on the future outlook of the potential Inhibikase Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Inhibikase Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 69.4 M | |
| Cash And Short Term Investments | 97.5 M |
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.